176 related articles for article (PubMed ID: 23146254)
1. Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study.
Bush G; Holmes J; Shin LM; Surman C; Makris N; Mick E; Seidman LJ; Biederman J
Psychiatry Res; 2013 Jan; 211(1):88-91. PubMed ID: 23146254
[TBL] [Abstract][Full Text] [Related]
2. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task.
Bush G; Spencer TJ; Holmes J; Shin LM; Valera EM; Seidman LJ; Makris N; Surman C; Aleardi M; Mick E; Biederman J
Arch Gen Psychiatry; 2008 Jan; 65(1):102-14. PubMed ID: 18180434
[TBL] [Abstract][Full Text] [Related]
3. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
4. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
6. The neurobiology of attention-deficit/hyperactivity disorder.
Chamberlain SR; Robbins TW; Sahakian BJ
Biol Psychiatry; 2007 Jun; 61(12):1317-9. PubMed ID: 17556026
[No Abstract] [Full Text] [Related]
7. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Husarova V; Bittsansky M; Ondrejka I; Dobrota D
Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
[TBL] [Abstract][Full Text] [Related]
9. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
Hammerness P; Georgiopoulos A; Doyle RL; Utzinger L; Schillinger M; Martelon M; Brodziak K; Biederman J; Wilens TE
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):493-9. PubMed ID: 19877973
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
[TBL] [Abstract][Full Text] [Related]
11. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
Chou TL; Chia S; Shang CY; Gau SS
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
CNS Drugs; 2010 Jan; 24(1):85-8. PubMed ID: 20030421
[TBL] [Abstract][Full Text] [Related]
13. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
Wilens TE; Hammerness P; Utzinger L; Schillinger M; Georgiopoulous A; Doyle RL; Martelon M; Brodziak K
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):485-92. PubMed ID: 19877972
[TBL] [Abstract][Full Text] [Related]
14. Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorder.
Robinson AM; Eggleston RL; Bucci DJ
Behav Neurosci; 2012 Dec; 126(6):762-71. PubMed ID: 23067385
[TBL] [Abstract][Full Text] [Related]
15. Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.
Bakken RJ; Paczkowski M; Kramer HP; Axelson AA; Williams DW; Malcolm SK; Sumner CR; Kelsey DK
Curr Med Res Opin; 2008 Feb; 24(2):449-60. PubMed ID: 18179733
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
17. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
Dell'Agnello G; Zuddas A; Masi G; Curatolo P; Besana D; Rossi A
CNS Drugs; 2009 Sep; 23(9):739-53. PubMed ID: 19689165
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
19. Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors.
Gamo NJ; Wang M; Arnsten AF
J Am Acad Child Adolesc Psychiatry; 2010 Oct; 49(10):1011-23. PubMed ID: 20855046
[TBL] [Abstract][Full Text] [Related]
20. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
